Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with fluvoxamine (moderate certainty).
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with fluvoxamine (low certainty).
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with hypericum (moderate certainty).
Fluoxetine probably leads to higher failure to complete ‐ total ‐ compared with hypericum (moderate certainty).
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with hypericum (moderate certainty).
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with hypericum (moderate certainty).
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with maprotiline (moderate certainty).
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with maprotiline (moderate certainty).
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with maprotiline (moderate certainty).
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with maprotiline (moderate certainty).
It is very uncertain whether fluoxetine changes failure to respond (reduction ≥ 50% on HDRS) compared with mianserin (very low certainty).
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with mianserin (moderate certainty).
It is very uncertain whether fluoxetine changes failure to complete ‐ inefficacy ‐ compared with mianserin (very low certainty).
It is very uncertain whether fluoxetine changes failure to complete ‐ side effects ‐ compared with mianserin (very low certainty).